| CAS NO: | 7491-74-9 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 2g | 电议 |
| 5g | 电议 |
| 10g | 电议 |
| 25g | 电议 |
| 50g | 电议 |
| 100g | 电议 |
| Molecular Weight (MW) | 142.16 |
|---|---|
| Formula | C6H10N2O2 |
| CAS No. | 7491-74-9 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 72 mg/mL (506.5 mM) |
| Water: 72 mg/mL (506.5 mM) | |
| Ethanol: <1 mg/mL | |
| Other info | Chemical Name: 1-Acetamido-2-pyrrolidinone InChi Key: SIXPSGNZQPKXTG-UHFFFAOYSA-N InChi Code: InChI=1S/C6H10N2O2/c1-5(9)7-8-4-2-3-6(8)10/h2-4H2,1H3,(H,7,9) SMILES Code: O=C1N(NC(C)=O)CCC1 |
| Synonyms | UCB-6215; Piracetam; Breinox; BRN-1526393; UCB6215; UCB 6215; BRN1526393; Ciclofalina; Cl871; BRN 1526393; Cl-871; Cl 871; EINECS 231-312-7; Euvifor; Gabacet; Genogris; Nootron; Nootropil; Nootropyl; Normabrain. |
| In Vitro | In vitro activity: Piracetam is able to significantly decrease the fusogenic and destabilising effect of Abeta 29-42, in a concentration-dependent manner. Preincubation of piracetam, at a piracetam/peptide ratio of 960, during 20 min before the addition of Abeta 29-42 prevents almost completely the mixture of the two fluorescent probes. Preincubation of piracetam with lipids prevents almost completely the release of calcein induced by the peptide in a dose-dependent fashion (piracetam/peptide ratios from 9.6 to 960). Piracetam (< 1.0 mM) preincubated with brain membranes enhances membrane fluidity in aged mice, rats and humans, as indicated by decreased anisotropy of the membrane-bound fluorescence probe 1,6-diphenyl-1,3,5-hexatriene (DPH). |
|---|---|
| In Vivo | Piracetam (300 mg/kg once daily) significantly increases membrane fluidity in some brain regions of young and aged rats, but has no measurable effect on membrane fluidity in the young rats. Piracetam (300 mg/kg daily for 6 weeks) improves active avoidance learning in the aged rats only and elevates membrane fluidity in all brain regions except the cerebellum in the aged rats. Piracetam (300 mg/kg daily for 6 weeks) also improves NMDA receptor density in the hippocampus and on muscarinic cholinergic receptor densities in the frontal cortex and the striatum and to a lesser extent in the hippocampus of rats. Piracetam (500 mg/kg p.o. for 14 days) elevates N-methyl-D-aspartate (NMDA) receptor density by about 20% and normalizes the enhanced affinity of L-glutamate for the NMDA receptor in aged mice. Piracetam-treated withdrawn rats has higher the number of synapses than that observed in nonpiracetam-treated and alcohol-fed animals by up to 20%, the mechanisms leading to the synaptic reorganization took place at the mossy fiber level. |
| Animal model | Male Wistar rats |
| Formulation & Dosage | Dissolved in saline; 300 mg/kg; oral gavage |
| References | Biochem Pharmacol. 1997 Jan 24;53(2):135-40; Pharmacopsychiatry. 1999 Mar;32 Suppl 1:10-6; Pharmacology. 1993 Oct;47(4):217-22. |
m.cnreagent.com